Research and Clinical Trials

Title  

CARE (Combating Antibiotic Resistance Enterobacteriaceae

Brief Description  

Patients with positive cultures for CRE (Cabapenem-Resistant Enterobacteriaceae) will be treated with either plazomicin or colistin (both with added meropenem or tigecycline) for up to 4 days. The study is looking to see if plazomicin is as good or better than the current treatment for CRE.

Who may be Eligible  

Ages 18-15; Positive culture for CRE; Not pregnant or breast feeding; Not have study defined prohibited co-infections; Not have antibiotic therapy for more than 72 hours prior to start; Not be on study disallowed mdications.

Start Date  

10/31/2015

IRB Number  

10-15-15B

Principal Investigator  

Horton, James

Contact Name  

Jessica

For More Information, Contact  Jessica  A, Kearney-Bryan
Phone:  (704) 355-0244  Fax:  (704) 446-7641  
Email:  Jessica.Kearney-bryan@atriumhealth.org
Address:1350 South Kings Drive 3rd Floor ID Clinic Charlotte, NC 28207